Loading...

We've got a brand new version of Simply Wall St! Try it out

Algernon Pharmaceuticals

CNSX:AGN
Snowflake Description

Adequate balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
AGN
CNSX
CA$5M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

Algernon Pharmaceuticals Inc., a clinical stage drug development company, focuses in the areas of non–alcoholic steatohepatitis, chronic kidney disease, and inflammatory bowel disease. The last earnings update was 55 days ago. More info.


Add to Portfolio Compare Print
  • Algernon Pharmaceuticals has significant price volatility in the past 3 months.
AGN Share Price and Events
7 Day Returns
-11.5%
CNSX:AGN
-5.9%
CA Pharmaceuticals
1.3%
CA Market
1 Year Returns
-50%
CNSX:AGN
-46.7%
CA Pharmaceuticals
-0.1%
CA Market
AGN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Algernon Pharmaceuticals (AGN) -11.5% -17.9% -47.7% -50% -77% -
CA Pharmaceuticals -5.9% -3.4% -24.8% -46.7% 217.3% 286.4%
CA Market 1.3% 4.2% 1.6% -0.1% 8.4% 5.7%
1 Year Return vs Industry and Market
  • AGN underperformed the Pharmaceuticals industry which returned -46.7% over the past year.
  • AGN underperformed the Market in Canada which returned -0.1% over the past year.
Price Volatility
AGN
Industry
5yr Volatility vs Market

Value

 Is Algernon Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Algernon Pharmaceuticals. This is due to cash flow or dividend data being unavailable. The share price is CA$0.115.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Algernon Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Algernon Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:AGN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-05-31) in CAD CA$-0.04
CNSX:AGN Share Price ** CNSX (2019-09-20) in CAD CA$0.12
Canada Pharmaceuticals Industry PE Ratio Median Figure of 13 Publicly-Listed Pharmaceuticals Companies 15.3x
Canada Market PE Ratio Median Figure of 539 Publicly-Listed Companies 14.14x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Algernon Pharmaceuticals.

CNSX:AGN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:AGN Share Price ÷ EPS (both in CAD)

= 0.12 ÷ -0.04

-2.77x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Algernon Pharmaceuticals is loss making, we can't compare its value to the CA Pharmaceuticals industry average.
  • Algernon Pharmaceuticals is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does Algernon Pharmaceuticals's expected growth come at a high price?
Raw Data
CNSX:AGN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.77x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Canada Pharmaceuticals Industry PEG Ratio Median Figure of 7 Publicly-Listed Pharmaceuticals Companies 1.56x
Canada Market PEG Ratio Median Figure of 245 Publicly-Listed Companies 1.02x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Algernon Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Algernon Pharmaceuticals's assets?
Raw Data
CNSX:AGN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-05-31) in CAD CA$0.11
CNSX:AGN Share Price * CNSX (2019-09-20) in CAD CA$0.12
Canada Pharmaceuticals Industry PB Ratio Median Figure of 151 Publicly-Listed Pharmaceuticals Companies 2.36x
Canada Market PB Ratio Median Figure of 2,457 Publicly-Listed Companies 1.43x
CNSX:AGN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:AGN Share Price ÷ Book Value per Share (both in CAD)

= 0.12 ÷ 0.11

1.01x

* Primary Listing of Algernon Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Algernon Pharmaceuticals is good value based on assets compared to the CA Pharmaceuticals industry average.
X
Value checks
We assess Algernon Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Algernon Pharmaceuticals has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Algernon Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Algernon Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
97.7%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Algernon Pharmaceuticals expected to grow at an attractive rate?
  • Unable to compare Algernon Pharmaceuticals's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Algernon Pharmaceuticals's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare Algernon Pharmaceuticals's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
CNSX:AGN Future Growth Rates Data Sources
Data Point Source Value (per year)
Canada Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 97.7%
Canada Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 56.5%
Canada Market Earnings Growth Rate Market Cap Weighted Average 12.6%
Canada Market Revenue Growth Rate Market Cap Weighted Average 5.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:AGN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:AGN Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-05-31 -2 -2
2019-02-28 -1 -2
2018-11-30 -1 -1
2018-08-31 -1 -1
2018-05-31 -1 -1
2018-02-28 -1 -1
2017-11-30 -1 -2
2017-08-31 -1 -2
2017-05-31 -1 -2
2017-02-28 -2 -2
2016-11-30 -2 -3
2016-08-31 -1 -7

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Algernon Pharmaceuticals is high growth as no earnings estimate data is available.
  • Unable to determine if Algernon Pharmaceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:AGN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Algernon Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:AGN Past Financials Data
Date (Data in CAD Millions) EPS *
2019-05-31 -0.04
2019-02-28 -0.04
2018-11-30 -0.04
2018-08-31 -0.03
2018-05-31 -0.04
2018-02-28 -0.05
2017-11-30 -0.06
2017-08-31 -0.07
2017-05-31 -0.08
2017-02-28 -0.08
2016-11-30 -0.16
2016-08-31 -0.39

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Algernon Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Algernon Pharmaceuticals's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Algernon Pharmaceuticals's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Algernon Pharmaceuticals's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Algernon Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Algernon Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Algernon Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Algernon Pharmaceuticals's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Algernon Pharmaceuticals does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Algernon Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Algernon Pharmaceuticals's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Algernon Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Algernon Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:AGN Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-05-31 -1.66 1.08 0.52
2019-02-28 -1.52 1.10 0.39
2018-11-30 -1.24 0.96 0.23
2018-08-31 -0.94 0.81 0.09
2018-05-31 -1.04 0.85 0.14
2018-02-28 -1.41 0.73 0.19
2017-11-30 -1.58 0.84 0.25
2017-08-31 -1.89 1.04 0.35
2017-05-31 -1.87 0.91 0.46
2017-02-28 -1.58 1.03 0.48
2016-11-30 -3.27 2.75 0.40
2016-08-31 -6.88 2.62 0.20
2016-05-31 -7.13 2.95 0.14
2015-08-31 -0.73 0.55 0.18

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Algernon Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Algernon Pharmaceuticals has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Algernon Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Algernon Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Algernon Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Algernon Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Algernon Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Algernon Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Algernon Pharmaceuticals has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Algernon Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Algernon Pharmaceuticals has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Algernon Pharmaceuticals Company Filings, last reported 3 months ago.

CNSX:AGN Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-05-31 5.40 0.00 0.50
2019-02-28 5.93 0.00 1.05
2018-11-30 6.23 0.00 1.36
2018-08-31 1.37 0.00 1.25
2018-05-31 1.46 0.00 1.28
2018-02-28 1.62 0.00 1.46
2017-11-30 1.40 0.00 1.22
2017-08-31 1.59 0.00 1.39
2017-05-31 1.89 0.00 1.64
2017-02-28 2.59 0.00 1.92
2016-11-30 2.92 0.00 2.14
2016-08-31 2.12 0.00 1.60
2016-05-31 2.56 0.00 1.89
2015-08-31 1.23 0.00 1.40
  • Algernon Pharmaceuticals has no debt.
  • Algernon Pharmaceuticals has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Algernon Pharmaceuticals has less than a year of cash runway based on current free cash flow.
  • Algernon Pharmaceuticals has less than a year of cash runway if free cash flow continues to reduce at historical rates of -11.7% each year.
X
Financial health checks
We assess Algernon Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Algernon Pharmaceuticals has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Algernon Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Algernon Pharmaceuticals dividends.
If you bought CA$2,000 of Algernon Pharmaceuticals shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Algernon Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Algernon Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:AGN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
North America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.8%
Canada Market Average Dividend Yield Market Cap Weighted Average of 334 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.1%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Algernon Pharmaceuticals has not reported any payouts.
  • Unable to verify if Algernon Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Algernon Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Algernon Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Algernon Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Algernon Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Algernon Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Algernon Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Chris Moreau
COMPENSATION CA$108,000
TENURE AS CEO 1.5 years
CEO Bio

Mr. Christopher J. Moreau, also known as Chris, has been Chief Executive Officer at Algernon Pharmaceuticals Inc. (f.k.a. Breathtec Biomedical Inc.) since March 1, 2018. Mr. Moreau has been the Chief Executive Officer at NASH Pharmaceuticals Inc., since December 2017. Mr. Moreau has been Consultant of RISE Life Science Corp. (f.k.a. Luminor Medical Technologies Inc. and Miraculins Inc.) since April 21, 2016 and served as its Chief Executive Officer and President from February 1, 2007 to April 21, 2016. Mr. Moreau served as Vice President of Business Development at RISE Life Science Corp. since March 2006 and as a Non Independent Director from May 30, 2011 to April 21, 2016. He joined RISE Life Science Corp. in March 2006. He served as the President of Advansis Capital Corporation, a privately held Canadian financial services provider. He serves in several senior executive roles in sales and marketing within the telecommunications and manufacturing sectors. He has over 20 years’ experience in the areas of business development, sales, marketing and operations management.

CEO Compensation
  • Insufficient data for Chris to compare compensation growth.
  • Chris's remuneration is lower than average for companies of similar size in Canada.
Management Team Tenure

Average tenure of the Algernon Pharmaceuticals management team in years:

1.9
Average Tenure
  • The average tenure for the Algernon Pharmaceuticals management team is less than 2 years, this suggests a new team.
Management Team

Chris Moreau

TITLE
Chief Executive Officer
COMPENSATION
CA$108K
TENURE
1.5 yrs

Michael S. Sadhra

TITLE
CFO & Director
COMPENSATION
CA$48K
AGE
50
TENURE
3.9 yrs

Alfred Wong

TITLE
Vice President of Corporate Development & Communications
COMPENSATION
CA$26K
TENURE
2.3 yrs

Mark Williams

TITLE
Chief Science Officer
TENURE
0.9 yrs
Board of Directors Tenure

Average tenure and age of the Algernon Pharmaceuticals board of directors in years:

3.9
Average Tenure
51
Average Age
  • The tenure for the Algernon Pharmaceuticals board of directors is about average.
Board of Directors

Michael S. Sadhra

TITLE
CFO & Director
COMPENSATION
CA$48K
AGE
50
TENURE
3.9 yrs

David Levine

TITLE
Director
AGE
52
TENURE
3.9 yrs

Raj Attariwala

TITLE
Director
AGE
51
TENURE
3.9 yrs

Arun Sanyal

TITLE
Member of Medical & Scientific Advisory Board
TENURE
0.5 yrs

Walter Reinisch

TITLE
Member of Medical & Scientific Advisory Board
TENURE
0.4 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
23. Jul 19 Buy Kulwant Malhi Individual 08. Feb 19 08. Feb 19 29,000 CA$0.31 CA$8,845
05. Jun 19 Buy Christopher Moreau Individual 22. Oct 18 24. May 19 780,000 CA$0.24 CA$7,200
09. Apr 19 Sell Michael S. Sadhra Individual 21. Mar 19 21. Mar 19 -117,343 CA$0.24 CA$-27,693
09. Jan 19 Buy BullRun Capital Inc. Company 19. Oct 18 23. Oct 18 5,647,170 CA$0.24 CA$35,321
09. Jan 19 Buy Kulwant Malhi Individual 18. Oct 18 18. Oct 18 11,500 CA$0.21 CA$2,415
24. Oct 18 Buy Alfred & Company Advisors Inc Company 19. Oct 18 19. Oct 18 105,000 CA$0.10 CA$10,500
X
Management checks
We assess Algernon Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Algernon Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Introducing Algernon Pharmaceuticals (CNSX:AGN), The Stock That Slid 64% In The Last Three Years

But long term Algernon Pharmaceuticals Inc. … Some Algernon Pharmaceuticals investors have already had a taste of the bitterness stocks like this can leave in the mouth. … Of course the long term matters more than the short term, and even great stocks will sometimes have a poor year.

Simply Wall St -

Did Changing Sentiment Drive Algernon Pharmaceuticals's (CNSX:AGN) Share Price Down A Painful 71%?

Algernon Pharmaceuticals didn't have any revenue in the last year, so it's fair to say it doesn't yet have a proven product (or at least not one people are paying for). … It seems likely some shareholders believe that Algernon Pharmaceuticals will significantly advance the business plan before too long. … When it last reported its balance sheet in November 2018, Algernon Pharmaceuticals had net cash of CA$1.1m.

Simply Wall St -

Company Info

Description

Algernon Pharmaceuticals Inc., a clinical stage drug development company, focuses in the areas of non–alcoholic steatohepatitis, chronic kidney disease, and inflammatory bowel disease. The company was formerly known as Breathtec Biomedical, Inc. and changed its name to Algernon Pharmaceuticals Inc. in February 2019. Algernon Pharmaceuticals Inc. is headquartered in Vancouver, Canada.

Details
Name: Algernon Pharmaceuticals Inc.
AGN
Exchange: CNSX
Founded:
CA$5,444,618
47,344,512
Website: http://algernonpharmaceuticals.com
Address: Algernon Pharmaceuticals Inc.
700 West Pender Street,
Suite 915,
Vancouver,
British Columbia, V6C 1G8,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX AGN Common Shares Canadian National Stock Exchange CA CAD 01. Feb 2016
OTCPK BTHC.F Common Shares Pink Sheets LLC US USD 01. Feb 2016
DB AGW Common Shares Deutsche Boerse AG DE EUR 01. Feb 2016
Number of employees
Current staff
Staff numbers
0
Algernon Pharmaceuticals employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/09/22 00:46
End of day share price update: 2019/09/20 00:00
Last earnings filing: 2019/07/29
Last earnings reported: 2019/05/31
Last annual earnings reported: 2018/08/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.